Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bleiberg

Showing results (131-140 of 159) with videos related to

Pageof 16
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1988
Controlled clinical trial for the treatment of patients with inoperable esophageal carcinoma: a study of the EORTC Gastrointestinal Tract Cancer Cooperative GroupA Roussel, J H Jacob, P Haegele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer StudyG Blijham, T Wagener, J Wils, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative GroupJ A Wils, H O Klein, D J Wagener, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1989
Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trialA Roussel, H Bleiberg, O Dalesio, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patientsBensmaïne, A de Gramont, S Brienza, et al.
Anti-Cancer Drugs|February 1, 1995
Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban GroupS J Van Belle, V F Cocquyt, H Bleiberg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in EuropeH Bleiberg, B Gerard, J Wils, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group)P Rougier, C van Pottelsberghe, T Kok, et al.
British Journal of Cancer|August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groupsG Freyer, P Rougier, R Bugat, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1996
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapyB Audhuy, P Cappelaere, M Martin, et al.
Pageof 16

Showing results (131-140 of 159) with videos related to

Sort By:
Pageof 16
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1988
Controlled clinical trial for the treatment of patients with inoperable esophageal carcinoma: a study of the EORTC Gastrointestinal Tract Cancer Cooperative GroupA Roussel, J H Jacob, P Haegele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer StudyG Blijham, T Wagener, J Wils, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative GroupJ A Wils, H O Klein, D J Wagener, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1989
Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trialA Roussel, H Bleiberg, O Dalesio, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patientsBensmaïne, A de Gramont, S Brienza, et al.
Anti-Cancer Drugs|February 1, 1995
Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban GroupS J Van Belle, V F Cocquyt, H Bleiberg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in EuropeH Bleiberg, B Gerard, J Wils, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group)P Rougier, C van Pottelsberghe, T Kok, et al.
British Journal of Cancer|August 17, 2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groupsG Freyer, P Rougier, R Bugat, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1996
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapyB Audhuy, P Cappelaere, M Martin, et al.
Pageof 16